Giulia Diluvio

Giulia Diluvio

Auto-generated profile, based on publicly available information

Giulia Diluvio

The DeWitt Daughtry Family Department of Surgery, Molecular Oncology Program, Miller School of Medicine, University of Miami, Miami, Florida

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2018 in Oncogenesis
Verified
Journal Article
Open access
PDF file
GDGiulia Diluvio
Giulia Diluvio
FGFrancesca Del Gaudio
Francesca Del Gaudio
MGMaria Valeria Giuli
Maria Valeria Giuli
GFGiulia Franciosa
Giulia Franciosa
EGEugenia Giuliani
Eugenia Giuliani
SCSaula Checquolo
Saula Checquolo
Notch dysregulation has been implicated in numerous tumors, including triple-negative breast cancer (TNBC), which is the breast cancer subtype with the worst clinical outcome. However, the importance of individual receptors in TNBC and their specific mechanism of action remain to be elucidated, even if recent findings suggested a specific role of activated-Notch3 in a subset of TNBCs. Epidermal growth factor receptor (EGFR) is overexpressed in TNBCs but the use of anti-EGFR agents (including tyrosine kinase inhibitors, TKIs) has not been approved for the treatment of these patients, as clinical trials have shown disappointing results. Resistance to EGFR blockers is commonly reported. Here we show that Notch3-specific inhibition increases TNBC sensitivity to the TKI-gefitinib in TNBC-resistant cells. Mechanistically, we demonstrate that Notch3 is able to regulate the activated EGFR membrane localization into lipid rafts microdomains, as Notch3 inhibition, such as rafts depletion, induces the EGFR internalization and its intracellular arrest, without involving receptor degradation. Interestingly, these events are associated with the EGFR tyrosine dephosphorylation at Y1173 residue (but not at Y1068) by the protein tyrosine phosphatase H1 (PTPH1), thus suggesting its possible involvement in the observed Notch3-dependent TNBC sensitivity response to gefitinib. Consistent with this notion, a nuclear localization defect of phospho-EGFR is observed after combined blockade of EGFR and Notch3, which results in a decreased TNBC cell survival. Notably, we observed a significant correlation between EGFR and NOTCH3 expression levels by in silico gene expression and immunohistochemical analysis of human TNBC primary samples. Our findings strongly suggest that combined therapies of TKI-gefitinib with Notch3-specific suppression may be exploited as a drug combination advantage in TNBC treatment.

5 April 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
AAAnnamil Alvarez-Trotta
Annamil Alvarez-Trotta
WGWilliam Guerrant
William Guerrant
LALuisana Astudillo
Luisana Astudillo
MLMohini Lahiry
Mohini Lahiry
GDGiulia Diluvio
Giulia Diluvio
ACAnthony J. Capobianco
Anthony J. Capobianco
In many human cancers, deregulation of the Notch pathway has been shown to play a role in the initiation and maintenance of the neoplastic phenotype. Aberrant Notch activity also plays a central role in the maintenance and survival of cancer stem cells (CSC), which underlie metastasis and resistance to therapy. For these reasons, inhibition of Notch signaling has become an exceedingly attractive target for cancer therapeutic development. However, attempts to develop Notch pathway–specific drugs have largely failed in the clinic, in part due to intestinal toxicity. Here, we report the discovery of NADI-351, the first specific small-molecule inhibitor of Notch1 transcriptional complexes. NADI-351 selectively disrupted Notch1 transcription complexes and reduced Notch1 recruitment to target genes. NADI-351 demonstrated robust antitumor activity without inducing intestinal toxicity in mouse models, and CSCs were ablated by NADI-351 treatment. Our study demonstrates that NADI-351 is an orally available and potent inhibitor of Notch1-mediated transcription that inhibits tumor growth with low toxicity, providing a potential therapeutic approach for improved cancer treatment.Significance: This study showcases the first Notch1-selective inhibitor that suppresses tumor growth with limited toxicity by selectively ablating cancer stem cells.

31 March 2023
Verified
Other
Open access
AAAnnamil Alvarez-Trotta
Annamil Alvarez-Trotta
WGWilliam Guerrant
William Guerrant
LALuisana Astudillo
Luisana Astudillo
MLMohini Lahiry
Mohini Lahiry
GDGiulia Diluvio
Giulia Diluvio
ACAnthony J. Capobianco
Anthony J. Capobianco
Sorting of OE33 cells by ALDH expression

31 March 2023
Verified
Other
Open access
AAAnnamil Alvarez-Trotta
Annamil Alvarez-Trotta
WGWilliam Guerrant
William Guerrant
LALuisana Astudillo
Luisana Astudillo
MLMohini Lahiry
Mohini Lahiry
GDGiulia Diluvio
Giulia Diluvio
ACAnthony J. Capobianco
Anthony J. Capobianco
Off target effect evaluation of NADI-351

31 March 2023
Verified
Other
Open access
AAAnnamil Alvarez-Trotta
Annamil Alvarez-Trotta
WGWilliam Guerrant
William Guerrant
LALuisana Astudillo
Luisana Astudillo
MLMohini Lahiry
Mohini Lahiry
GDGiulia Diluvio
Giulia Diluvio
ACAnthony J. Capobianco
Anthony J. Capobianco
IHC of EAC47 PDX treated with NADI-351 for 30 days

31 March 2023
Verified
Other
Open access
AAAnnamil Alvarez-Trotta
Annamil Alvarez-Trotta
WGWilliam Guerrant
William Guerrant
LALuisana Astudillo
Luisana Astudillo
MLMohini Lahiry
Mohini Lahiry
GDGiulia Diluvio
Giulia Diluvio
ACAnthony J. Capobianco
Anthony J. Capobianco
NADI-351 inhibits recruitment of Notch1 to the NTC and to the HES1 promoter